Indication
For treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results
Medicine details
- Medicine name:
- levodopa/carbidopa/entacapone (Lecigon)
- SMC ID:
- SMC2507
- Pharmaceutical company
- Britannia Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- 10 January 2023
- Patient group submission deadline:
- 31 October 2022